Year End 2022

SARC is dedicated to driving collaborations among individuals and organizations worldwide committed to discovering, developing, and delivering the latest and most promising treatments for all types of sarcomas.

View this email in your browser


2022: SARC Year In Review

With gratitude to all our collaborators and supporters, and acknowledging the many challenges and opportunities facing SARC and sarcoma stakeholders, here follow a few of SARC's achievements and milestones for 2022:

  • Established new strategic role of Chief Medical Officer, (complementing the Chief Scientific Officer position established and filled the prior year); initiated national search learn more
  • Scott Okuno MD (Mayo Clinic Rochester) appointed as Chief Medical Officer learn more
  • Held well-attended Semiannual Membership Meetings learn more at 1) pre-ASCO Annual Meeting (Chicago) and 2) CTOS Annual Meeting (Vancouver BC)
  • CTOS 2022 Annual Meeting learn more two SARC-sponsored trials selected for oral presentations in Vancouver BC: [a] SARC031 learn more Selumetinib + Sirolimus in malignant peripheral nerve sheath tumors (PI Aerang Kim MD PhD, Children's National Medical Center & Co-PI Brigitte Widemann MD, National Cancer Institute), and [b] SARC033 / ETCTN NCI 10015 learn more Trametinib in epithelioid hemangioendothelioma (PI Scott Schuetze, U. of Michigan)
  • As COVID eased, enrollment accelerated on the six active SARC-sponsored clinical trials learn more in the US and globally; we completed enrollment for SARC031 learn more and for the Phase I (Ph II now enrolling) cohort for SARC037 learn more (PI Patrick Grohar, Children's Hospital of Philadelphia)
  • Published results of SARC024 in Cancer Medicine - "A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results", Steven Attia (Mayo Clinic Florida), Robert Maki (Penn Medicine), et al. learn more
  • SARC's "crown jewel" Career Development Award (CDA) learn more, co-lead by Karla Ballman PhD (SARC Statistician; Weill Cornell) and Jonathan Fletcher (SARC Chief Scientific Officer; Brigham and Women's Hospital), awarded to Lillian Guenther MD PhD (St. Jude Children's Research Hospital) learn more
  • Developed and launched Catalyst Program learn more, lead by Keila E. Torres MD PhD (MD Anderson Cancer Center) and Jonathan Fletcher MD (SARC Chief Scientific Officer; Brigham and Women's Hospital), combining financial support for small-scale sarcoma research projects with monthly expert coaching sessions; Joanna Przybyl PhD (McGill) inaugural recipient for "Multi-omic circulating tumor DNA testing in leiomyosarcoma” learn more
  • Launched SARCTALK learn more as a podcast series (Spotify, Apple, YouTube), hosted by Dr. Scott Okuno (SARC Chief Medical Officer) featuring conversations with sarcoma investigators and patients on research and ways to accelerate progress; the inaugural episode listen featured William Tap MD (Memorial Sloan Kettering Cancer Center) & Brian Van Tine MD PhD (Washington University in St. Louis; 2012 CDA recipient), and the second podcast listen spotlighted Inga-Marie Schaefer MD (Brigham and Women's Hospital; 2019 CDA recipient)
  • Expanded the SARC Research Advocacy Council learn more


You can reach SARC by phone at 734.930.7600 or email at


SARC (Sarcoma Alliance for Research through Collaboration) is a non-profit organization dedicated to the development and support of research for the prevention, treatment, and cure of sarcoma – a cancer of the bone and connective tissues of the body.

SARC was formed in 2003 to conduct innovative and rigorous sarcoma research to advance the care of patients. Today, SARC collaborators include field-leading sarcoma physicians and researchers across the globe, working together to develop new strategies to improve outcomes for sarcoma patients.

Facebook  Twitter  Instagram